Sometimes, we can answer these questions by marshaling technologies that are already available, either in the lab or in the clinic, and applying them in clever ways. Sometimes, however, the answers point to new biology and demand new ways of assessing that biology-and in those instances, new technologies must be developed. But the target is always the biology. In this sense, the question of whether visualization of cortical lesions with magnetic resonance imaging (MRI) should be improved is fundamentally misplaced.
In their essays, Geurts and Chard, and Mainero and Granberg, implicitly recognize this tension. Geurts and Chard state explicitly that "we should keep in mind the reasons" for improving visualization of cortical lesions and suggest that such reasons should not include the ability to count ever higher numbers of lesions. Mainero and Granberg concur that lesion count per se is not the target, instead putting front and center the question of "pathological specificity" and pathophysiology. In these claims, both pairs of authors are right.
Both conceptually and practically, cortical lesions present an interesting challenge. Conceptually, the cortex-like the white matter-is not a uniform structure, despite its relatively homogeneous appearance on clinical MRI scans. It has unique cytoarchitecture and myeloarchitecture, and both architectures vary across gyri, lobules, and lobes. The cortex has a complex relationship with the underlying white matter and overlying leptomeninges, and the network of blood vessels that supply and drain the cortex is both intricate and spatially heterogeneous. All of these factors may play a role in whether, and how, cortical lesions develop. The most obvious example involves the subpial lesions, which radiate downward from the pial surface and often flank both banks of a single sulcus; the topography of such lesions is obviously different from that of the leukocortical and small intracortical lesions.
Indeed, one might argue that lesion classification should not depend on the (coarsely defined) tissue type in which a given lesion appears, but rather on that lesion's pathophysiology. In this sense, it would be much more natural to group leukocortical and small intracortical lesions with their white matter counterparts, as all of these lesions form around small parenchymal veins. Subpial lesions, while subsuming the tiny penetrating veins of the cortex, do not arise from them, but rather appear to relate to inflammation within the leptomeninges; for this reason, subpial lesions are in a class of their own. Whereas a great deal is known about the pathophysiology of perivenular lesions, both from human tissue and from animal models, very little is understood about how subpial lesions develop-whether they all arise from leptomeningeal inflammation; whether such inflammation is transient or persistent (or a bit of each); whether they occur in young people early in the disease (like white matter lesions) or continue to appear throughout a lifetime of MS; whether they develop all at once or expand slowly over years, reaching ever deeper layers of the cortex and possibly engendering ever more disability; and, importantly, whether they can be modulated by existing disease-modifying therapies.
It should of course be acknowledged that there are some senses in which cortical lesions are properly a group unto themselves. For example, the blood-brain barrier is rarely abnormal in cortical lesions, but leakage of intravenously injected MRI contrast agents is a nearly universal finding in acute white matter lesions. The therapeutic implications of this interesting observation are probably profound. And as a class, cortical lesions are much harder to see by MRI than their white matter counterparts, presumably because of a combination of the relatively small amount of normal myelin within the cortex and the paucity of inflammation and edema within cortical MS lesions. Indeed, the latter point forms the basis of the question at hand, because cortical lesions have been difficult to see well and reliably, as both Mainero and Granberg, and Geurts and Chard, point out.
The accumulated evidence gathered over many decades, but in particular the last two, suggests that cortical lesions form an important piece of the MS puzzle, and understanding them will have a profound impact on the ultimate answers to all of the questions presented at the outset of this commentary. The measure of a new technique-whether it is simple or fancy, mundane or clever, cheap or expensive-should always be taken in this context.
